Status:
ACTIVE_NOT_RECRUITING
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
Lead Sponsor:
University of Michigan Rogel Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Thyroid Cancer
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The study will include 50 patients newly diagnosed with low-risk thyroid cancer ranging from 18-80 years of age. After scheduling their surgeon visit, the investigators will enroll patients and measur...
Eligibility Criteria
Inclusion
- Age 18 to 80 years
- Low risk papillary thyroid cancer or highly suspicious for cancer
- Low risk papillary thyroid cancer
- cT1-2: Tumor size 4 cm or smaller and limited to the thyroid on ultrasound
- cN0: No evidence of lymph node metastasis on ultrasound
- cM0: No evidence of distant metastasis on imaging
- Highly suspicious for cancer
- Cytology meeting Bethesda V or Bethesday III or IV with molecular testing indicating a 70% risk of greater of thyroid cancer
- Nodule size 4 cm and smaller
- Limited to the thyroid on ultrasound
- No evidence of suspicious lymph nodes
- No evidence of thyroid cancer outside of the neck
- Referred for surgical consultation.
Exclusion
- History of previous thyroid cancer or thyroid surgery and parathyroid surgery
- Non-English speaking
- Deaf
- Subject Selection (for Surgeons)
- Surgeon Inclusion Criteria
- Performs at least one thyroid surgery annually on adults
- Credentialed at Michigan Medicine
- Surgeon Exclusion Criteria
- None
Key Trial Info
Start Date :
September 18 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06073223
Start Date
September 18 2023
End Date
December 1 2025
Last Update
November 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Michigan Cancer Center
Ann Arbor, Michigan, United States, 48109